

# Discussion themes

- Underfunding of the sector (Pharmac, DHBs, etc) impacts on clinical trials
- Tax credits
- DHB efficiency/capability and prioritisation of clinical research
- KPIs for research in DHBs
- EPA process when GMOs are involved in studies
- Data – big data, data access
- Reimbursement model
- ACC

# Opportunities for input

- HRC's consultation on NZ's first prioritisation vehicle for health research closes 1 April
  - [www.hrc.govt.nz](http://www.hrc.govt.nz)
- MoH consultation on Therapeutic Products Regulatory Scheme closes 18 April
  - [www.consult.health.govt.nz](http://www.consult.health.govt.nz)
- NH4HR submission plus individual/organisational submissions